FTC says PBMs ‘exercise vast control’ over healthcare, but stops short of calling for antitrust action

Drew Armstrong

Executive Editor

Federal antitrust regulators issued a report describing the PBM industry as highly concentrated among a handful of companies that use their market power to put …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FTC says PBMs ‘exercise vast control’ over healthcare, but stops short of calling for antitrust action

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FTC says PBMs ‘ex­er­cise vast con­trol’ over health­care, but stops short of call­ing for an­titrust ac­tion

Executive Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FTC says PBMs ‘exercise vast control’ over healthcare, but stops short of calling for antitrust action